Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind Studies

Kim Papp; Jacek Szepietowski; Leon Kircik; Darryl Toth; Michael Kuligowski; May Venturanza; Kang Sun; Eric Simpson

doi:10.25251/skin.5.supp.8

Kim Papp

Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada

Jacek Szepietowski

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland

Leon Kircik

Icahn School of Medicine at Mount Sinai, New York, NY, USA

Darryl Toth

XLR8 Medical Research and Probity Medical Research, Windsor, ON, Canada

Michael Kuligowski

Incyte Corporation, Wilmington, DE, USA

May Venturanza

Incyte Corporation, Wilmington, DE, USA

Kang Sun

Incyte Corporation, Wilmington, DE, USA

Eric Simpson

Oregon Health & Science University, Portland, OR, USA

Keywords

Atopic Dermatitis, Janus Kinase Inhibitor, Ruxolitinib, Efficacy, Safety

Abstract

Abstract not available.

References

1. Wei W, et al. J Dermatol. 2018;45(2):150-157.

2. Silverberg JI, et al. Ann Allergy Asthma Immunol. 2018;121(3):340-347.

3. Bao L, et al. JAKSTAT. 2013;2(3):e24137.

4. Oetjen LK, et al. Cell. 2017;171(1):217-228.

5. Quintas-Cardama A, et al. Blood. 2010;115(15):3109-3117. 6. Kim BS, et al. J Allergy Clin Immunol. 2020;145(2):572-582.

Poster PDF

Published

Jan 1, 2021

DOI https://doi.org/10.25251/skin.5.supp.8

How to Cite

[1]

Papp, K., Szepietowski, J., Kircik, L., Toth, D., Kuligowski, M., Venturanza, M., Sun, K. and Simpson, E. 2021. Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind Studies. SKIN The Journal of Cutaneous Medicine. 5, 1 (Jan. 2021), s8. DOI:https://doi.org/10.25251/skin.5.supp.8.

Issue

Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)

Section

Atopic Dermatitis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Zoe Draelos, Emil Tanghetti, Linda Stein Gold, Hilary Baldwin, Leon Kircik, Eric Guenin, Tazarotene 0.045% Lotion for Acne: Formulation, Application Characteristics, and Clinical Efficacy and Safety , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Jonathan Silverberg, Sebastien Barbarot, Melinda Gooderham, Jan Simon, Eric Simpson, Azra Kurbasic, Christina Olsen, Michael Cork, Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Andrew Blauvelt, Jacek Szepietowski, Kim Papp, Eric Simpson, Jonathan Silverberg, Brian Kim, Shawn Kwatra, Michael Kuligowski, May Venturanza, Kang Sun, Leon Kircik, Itch-Free State in Patients With Atopic Dermatitis Treated With Ruxolitinib Cream , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Karen Veverka, Jes Hansen, Maria Yaloumis, Leon Kircik, Linda Stein Gold, Treatment Success in Mild Psoriasis Patients With Fixed-Combination Calcipotriene and Betamethasone Dipropionate (Cal/BD) Foam: Results From the PSO-FAST Trial , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Stephan Weidinger, Jonathan Silverberg, Darryl Toth, Thomas Bieber, Andrew Alexis, Boni Elewski, Andrew Pink, DirkJan Hignen, Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Kristian Reich, Eric Simpson, Richard Langley, Richard Warren, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Le Gjerum, Anna Carlsson, Melinda Gooderham, Andreas Pinter, Marjolein De Bruin Weller, Andrew Blauvelt, Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Eric Simpson, Lawrence Eichenfield, Melinda Gooderham, Mercedes E. Gonzalez, Adelaide Hebert, Kim Papp, Vimal H. Prajapati, David Krupa, Patrick Burnett, David Berk, Robert Higham, Efficacy and Safety of Roflumilast Cream 0.15% in Adults and Children Aged ≥6 Years With Mild to Moderate Atopic Dermatitis in Two Phase 3 Trials (INTEGUMENT-1 and INTEGUMENT-2) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 4 (2023): July Issue & Posters from FCPANP 23
Nicholas Bodor, Adam Friedman, Stacy Smith, James Del Rosso, Janet Dubois, Adelaide Herbert, Tory Sullivan, Zakiya Rice, Joe Gorlick, Leon Kircik, Lawrence Green, Brandon Kirsch, Deepak Chadha, Investigating Treatment of Primary Axillary Hyperhidrosis With a Topical Retrometabolic Anticholinergic Drug , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Linda Stein Gold, MD, Leon H. Kircik, MD, Emil A Tanghetti, MD, Hilary Baldwin, MD, Zoe D. Draelos, MD, Michael Gold, MD, Edward Lain, MD, MBA, David M Pariser, MD, Neil Sadick, MD, Radhakrishnan Pillai, PhD, Varsha Bhatt, PhD, Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Randomized Phase 2 and Phase 3 Studies of the First Triple-Combination Drug , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Leon Kircik, Zoe Draelos, Eric Guenin, Tazarotene 0.045% Lotion for Truncal Acne: Efficacy, Safety, and Spreadability , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 4 (2022): July 2022 Issue

<< < 2 3 4 5 6 7 8 9 10 11 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)